
    
      The study will evaluate the effect of two intravenous dose regimens of benralizumab
      (MEDI-563) (0.3 milligram per kilogram [mg/kg] of body weight and 1.0 mg/kg of body weight)
      on the proportion of adult subjects with asthma exacerbations (relapse and de novo) who
      required an urgent healthcare visit for treatment of an acute asthma exacerbation.
    
  